These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 21880260)
1. [Histone methyltransferases: a new class of therapeutic targets in cancer treatment?]. Chaib H; Prébet T; Vey N; Collette Y Med Sci (Paris); 2011; 27(8-9):725-32. PubMed ID: 21880260 [TBL] [Abstract][Full Text] [Related]
5. [Targeted epigenetic therapy of cancer. Achievements and perspectives]. Valdespino-Gómez VM; Valdespino-Castillo VE Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455 [TBL] [Abstract][Full Text] [Related]
6. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Morera L; Lübbert M; Jung M Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667 [TBL] [Abstract][Full Text] [Related]
7. Epigenetic cancer therapy: Proof of concept and remaining challenges. Mund C; Lyko F Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865 [TBL] [Abstract][Full Text] [Related]
8. Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies? Michalak EM; Visvader JE Mol Oncol; 2016 Dec; 10(10):1497-1515. PubMed ID: 27717710 [TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors. Marks PA; Richon VM; Miller T; Kelly WK Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890 [TBL] [Abstract][Full Text] [Related]
10. Cancer treatment of the future: inhibitors of histone methyltransferases. Spannhoff A; Sippl W; Jung M Int J Biochem Cell Biol; 2009 Jan; 41(1):4-11. PubMed ID: 18773966 [TBL] [Abstract][Full Text] [Related]
11. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment. Zagni C; Chiacchio U; Rescifina A Curr Med Chem; 2013; 20(2):167-85. PubMed ID: 23210854 [TBL] [Abstract][Full Text] [Related]
12. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Mohammad HP; Barbash O; Creasy CL Nat Med; 2019 Mar; 25(3):403-418. PubMed ID: 30842676 [TBL] [Abstract][Full Text] [Related]
14. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. Lee SH; Kim J; Kim WH; Lee YM Oncogene; 2009 Jan; 28(2):184-94. PubMed ID: 18850007 [TBL] [Abstract][Full Text] [Related]
15. Histone deacetylases and cancer: causes and therapies. Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574 [TBL] [Abstract][Full Text] [Related]
16. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893 [TBL] [Abstract][Full Text] [Related]